Every year, nearly a half-billion people become infected with malaria. Though widely accepted as a preventable disease, it still kills more than one-million people throughout the world annually, disproportionately affecting children and pregnant women, mainly in Africa. Malaria-related death and illness place a tremendous burden on already strained health care systems and fragile economies in developing nations.
With malaria programs in more than 25 countries, Management Sciences for Health (MSH) works with public and private partners to improve access to and use of quality health services, including essential medicines and commodities. At the local level, MSH works with national health systems and organizations to strengthen their capacity to implement effective malaria control and prevention programs. MSH is also engaged in malaria policy dialogue and works at the global, regional, and national levels to support international initiatives, which include Roll Back Malaria (RBM); the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM); and the President's Malaria Initiative (PMI).
Our approach is marked by experience and expertise in the following areas:
With malaria programs in more than 25 countries, Management Sciences for Health (MSH) works with public and private partners to improve access to and use of quality health services, including essential medicines and commodities. At the local level, MSH works with national health systems and organizations to strengthen their capacity to implement effective malaria control and prevention programs. MSH is also engaged in malaria policy dialogue and works at the global, regional, and national levels to support international initiatives, which include Roll Back Malaria (RBM); the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM); and the President's Malaria Initiative (PMI).
Our approach is marked by experience and expertise in the following areas:
- health systems strengthening;
- community-based diagnosis and treatment;
- supporting the design and implementation of policies to deliver the most effective antimalarial drugs (currently artemisinin-based combination therapy (ACT);
- commodity quantification for national and decentralized health systems;
- assessment and support to supply systems at both the national and community levels;
- support to the RBM Partnership for global improved supply and use of quality antimalarials and related supplies.